123I-mIBG imaging predicts functional improvement and clinical outcome in patients with heart failure and CRT implantation

Curcio, Antonio; Cascini, Giuseppe Lucio; Rosa, Salvatore De; Pasceri, Eugenia; Veneziano, Claudia; Cipullo, Stefania; Saccomanno, Milena; Santarpia, Giuseppe; Cuda, Giovanni; Indolfi, Ciro

doi:10.1016/j.ijcard.2016.01.131

Cited by 9 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, angiotensin‐converting enzyme inhibitors, beta‐receptor antagonists, spironolactone, and cardiac resynchronization therapy have shown to improve the cardiac function and prognosis. These beneficial effects were associated with an increased H/M and a decreased WR 7–11 . Thus, the degree of improvement in MIBG parameters by the MitraClip procedure for MR might predict the positive effect on prognosis.…”

Section: Discussionmentioning

confidence: 96%

“…These beneficial effects were associated with an increased H/M and a decreased WR. [7][8][9][10][11] Thus, the degree of improvement in MIBG parameters by the MitraClip procedure for MR might predict the positive effect on prognosis. In patients with HF due to MR, MIBG scintigraphy may be useful in evaluating the effectiveness and the risk for cardiovascular events after MitraClip therapy.…”

Section: Discussionmentioning

confidence: 99%

“…[4][5][6] In patients with chronic HF, specific medical therapy and cardiac devices have contributed to the improvement in CSN activity, cardiac function, and clinical outcome. [7][8][9][10][11] Recently, percutaneous mitral valve repair using MitraClip system (Abbot Vascular, Santa Clara, California) for moderate to severe (3+) or severe (4+) mitral regurgitation (MR) is relatively safe and effective in patients with HF. 12,13 Many studies have investigated the clinical outcome, laboratory data, haemodynamic changes, or cardiac function assessed by transthoracic echocardiography (TTE) in patients who underwent the MitraClip procedure.…”

Section: Introductionmentioning

confidence: 99%

“…In patients with chronic HF, specific medical therapy and cardiac devices have contributed to the improvement in CSN activity, cardiac function, and clinical outcome 7–11 . Recently, percutaneous mitral valve repair using MitraClip system (Abbot Vascular, Santa Clara, California) for moderate to severe (3+) or severe (4+) mitral regurgitation (MR) is relatively safe and effective in patients with HF 12,13 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Changes in cardiac sympathetic nerve activity on ¹²³I‐metaiodobenzylguanidine scintigraphy after MitraClip therapy

et al. 2021

View full text Add to dashboard Cite

Aims In patients with heart failure, over-activation of the cardiac sympathetic nerve (CSN) function is associated with severity of heart failure and worse outcome. The effects of MitraClip therapy on the CSN activity in patients with mitral regurgitation (MR) remained unknown. In this study, we evaluated the impact of the MitraClip therapy on CSN activity assessed by 123 I-metaiodobezylguanidine (MIBG) scintigraphy. Methods and results We enrolled consecutive patients with moderate-to-severe (3+) or severe (4+) MR who were scheduled to undergo MitraClip procedure in this prospective observational study. MIBG scintigraphy was performed at baseline and 6 months after the MitraClip procedure to evaluate the heart-mediastinum ratio and washout rate (WR). Changes in these MIBG parameters were analysed. Of the 13 consecutive patients, 10 were successfully treated with MitraClip procedure and completed follow-up assessment. With regard to the MIBG parameters, changes in the early and delayed heart-mediastinum ratio from baseline to 6 months were not significant (2.16 ± 0.42 to 2.06 ± 0.34, P = 0.38 and 1.87 ± 0.39 to 1.83 ± 0.39, P = 0.43, respectively), whereas WR was significantly decreased (38.6 ± 3.9% to 32.6 ± 3.94%, P = 0.002). Conclusions The CSN activity of the WR on MIBG imaging was improved 6 months after MitraClip therapy in patients with 3+ or 4+ MR.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in cardiac sympathetic nerve activity on ¹²³I‐metaiodobenzylguanidine scintigraphy after MitraClip therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Возможность сцинтиграфии сердца с 123 I-МИБГ в прогнозировании ответа на СРТ изучали Curcio A. и соавт. [61]. Через , в которое вошли пациенты с ХСН (n=121, ФВ ЛЖ <24 %, ФК СН III-IV) до и после проведения СРТ.…”

Section: сцинтиграфия миокарда с 123 I-мибг в оценке результатов срт unclassified

123 I-MIBG scintigraphy in the assessment of heart failure prognosis and effectiveness of cardiac resynchronization therapy

et al. 2020

View full text Add to dashboard Cite

Cardiac resynchronization therapy (CRT) is one of the methods of treating patients with chronic heart failure, which can reduce the mortality rate of this group. Scintigraphic assessment of sympathetic myocardial innervation allows us to evaluate the heart failure prognosis and the effectiveness of interventional treatment. The method is based on use of the radiopharmaceutical 123 I-methiodiobenzylguanidine (123 I-MIBG), which is a structural analogue of norepinephrine and is able to selectively accumulate in the sympathetic nerve endings. This review includes a brief description of norepinephrine metabolism and pharmacokinetics of 123 I-MIBG in the sympathetic nerve ending, a brief description of the study methodology and the clinical significance of this method in patients with heart failure. Particular attention is paid to the possibilities of using this method in patients with severe chronic heart failure before and after CRT.

show abstract

Prognostic effect and modulation of cardiac sympathetic function in heart failure patients treated with cardiac resynchronization therapy

Moreira

Abreu

Portugal

et al. 2020

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

show abstract

123I-mIBG imaging predicts functional improvement and clinical outcome in patients with heart failure and CRT implantation

Cited by 9 publications

References 10 publications

Changes in cardiac sympathetic nerve activity on ¹²³I‐metaiodobenzylguanidine scintigraphy after MitraClip therapy

Changes in cardiac sympathetic nerve activity on ¹²³I‐metaiodobenzylguanidine scintigraphy after MitraClip therapy

123 I-MIBG scintigraphy in the assessment of heart failure prognosis and effectiveness of cardiac resynchronization therapy

Prognostic effect and modulation of cardiac sympathetic function in heart failure patients treated with cardiac resynchronization therapy

Contact Info

Product

Resources

About

123I-mIBG imaging predicts functional improvement and clinical outcome in patients with heart failure and CRT implantation

Cited by 9 publications

References 10 publications

Changes in cardiac sympathetic nerve activity on 123I‐metaiodobenzylguanidine scintigraphy after MitraClip therapy

Changes in cardiac sympathetic nerve activity on 123I‐metaiodobenzylguanidine scintigraphy after MitraClip therapy

123 I-MIBG scintigraphy in the assessment of heart failure prognosis and effectiveness of cardiac resynchronization therapy

Prognostic effect and modulation of cardiac sympathetic function in heart failure patients treated with cardiac resynchronization therapy

Contact Info

Product

Resources

About

Changes in cardiac sympathetic nerve activity on ¹²³I‐metaiodobenzylguanidine scintigraphy after MitraClip therapy

Changes in cardiac sympathetic nerve activity on ¹²³I‐metaiodobenzylguanidine scintigraphy after MitraClip therapy